Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study

Journal of Thrombosis and Thrombolysis

Volumn 43, Issue 2, 2017, Pages 166-171

  Mantha, Simon ^a   Laube, Eva ^a   Miao, Yimei ^a   Sarasohn, Debra M ^a   Parameswaran, Rekha ^a   Stefanik, Samantha ^a   Brar, Gagandeep ^b   Samedy, Patrick ^a   Wills, Jonathan ^a   Harnicar, Stephen ^a   Soff, Gerald A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Anticoagulation; Cancer; Rivaroxaban; Venous thromboembolism

Indexed keywords

RIVAROXABAN; ANTICOAGULANT AGENT;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY FAILURE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MORTALITY; PROSPECTIVE STUDY; QUALITY CONTROL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; COMPLICATION; MIDDLE AGED; NEOPLASMS; RECURRENT DISEASE; STANDARDS; TREATMENT OUTCOME; VALIDATION STUDY;

ANTICOAGULANTS; COHORT STUDIES; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RECURRENCE; RIVAROXABAN; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84989209067     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-016-1429-1     Document Type: Article

References (17)

1. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632–634. doi:10.1111/j.1538-7836.2007.02374.x
2. Khorana AA, Dalal M, Lin J, Connolly GC (2013) Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 119(3):648–655. doi:10.1002/cncr.27772
3. Khorana AA, Carrier M, Garcia DA, Lee AY (2016) Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis 41(1):81–91. doi:10.1007/s11239-015-1313-4
4. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M, Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer Investigators (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2):146–153. doi:10.1056/NEJMoa025313
5. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G, LITE Trial Investigators (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119(12):1062–1072. doi:10.1016/j.amjmed.2006.02.022
6. Lee AY, Peterson EA (2013) Treatment of cancer-associated thrombosis. Blood 122(14):2310–2317. doi:10.1182/blood-2013-04-460162
7. 2016 ASP Drug Pricing Files http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2016ASPFiles.html. Accessed 2 Dec 2016
8. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, RE-COVER Study Group (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361 (24):2342–2352. doi:10.1056/NEJMoa0906598
9. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510. doi:10.1056/NEJMoa1007903
10. EINSTEIN-PE Investigators, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287–1297. doi:10.1056/NEJMoa1113572
11. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808. doi:10.1056/NEJMoa1302507
12. Hokusai VTEI, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406–1415. doi:10.1056/NEJMoa1306638
13. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694. doi:10.1111/j.1538-7836.2005.01204.x
14. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31–41
15. Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, Bergqvist D, Turpie AG, Ortel TL, Spyropoulos AC, Pabinger I, Kakkar AK (2015) Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost 13(6):1028–1035. doi:10.1111/jth.12923
16. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS, EINSTEIN Investigators (2013) Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 11(1):21. doi:10.1186/1477-9560-11-21
17. Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, Raskob GE, Weitz JI, Yamabe T (2015) Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 13(12):2187–2191. doi:10.1111/jth.13153